AdvisorShares Vice ETF

NYSEARCA: ACT
$26.45
-$0.34 (-1.3%)
Closing price September 17, 2020
A new ETF that includes only U.S. firms operating in the legal cannabis market made its first appearance on Wednesday.
Many investors are focused on getting the jump on the cannabis industry, but they aren’t alone. With this increased speculation, there is added risk that has to be considered.
The ETF universe includes a variety of funds that allow investors to share in the spoils of legal gambling, smoking (tobacco and marijuana), and beer and spirits consumption. Investing in sin can pay...
With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged. Investors can use a number of ETFs to invest in the future of cannabis.
Allergan has issued a press release that confirms some of the rumors floating in the market that it has been approached by Pfizer.
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
American Airlines will be the newest addition to the S&P 500, taking the place of Allergan.
All indexes rebalance on a quarterly basis. 24/7 Wall St. screened a recent Jefferies report for the stocks that will see the most trading on Friday's rebalance.
Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based on a new price for Salix shares.
A new report from UBS shows some serious changes made to the firm's Equity Focus list for March.
Actavis launched second-largest ever bond sale Monday to raise $21 billion to pay for its acquisition of Allergan.
The UBS CIO Wealth Management team makes a good case that investors should consider the stocks in the firm's Quality Growth at a Reasonable Price (Q-GARP) portfolio.
24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.
Here is a look at the top performers for 2014, nine stocks that have doubled and have a current market cap of at least $5 billion.
While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in America.